Page |1
NUR 521 Advanced Pharmacology – Complete Practice
Test Bank (2026)
Instructions: Detailed rationales are provided to reinforce advanced concepts.
EXAM 1: Pharmacokinetics, Pharmacodynamics, & Drug Metabolism
1. A patient with renal impairment is prescribed a drug that is primarily
eliminated unchanged by the kidneys. Which pharmacokinetic parameter will be
most significantly altered?
A) Volume of distribution (Vd)
B) Bioavailability
C) Half-life (t½)
D) Peak plasma concentration (Cmax)
Answer: C
Rationale: Half-life (t½) is directly affected by clearance (CL) and volume of
distribution (Vd): t½ = (0.693 × Vd) / CL. If renal clearance is reduced, the drug's
half-life will increase, leading to accumulation and potential toxicity. This is why
dose adjustments are required in renal impairment.
2. A drug with a high therapeutic index (TI) is characterized by:
A) A narrow margin between the effective dose and the toxic dose
B) A wide margin between the effective dose and the toxic dose (e.g., TI > 10)
C) A low potency
D) A short half-life
Answer: B
Rationale: The therapeutic index (TI) is the ratio of the toxic dose (TD50) to the
effective dose (ED50). A high TI (e.g., penicillin, which has a TI > 100) means the
drug is very safe, as the toxic dose is far higher than the effective dose. A low TI
(e.g., digoxin, warfarin) indicates a narrow safety margin and requires strict
monitoring.
, Page |2
3. A patient is taking a drug with a half-life of 8 hours. Approximately how long
will it take to reach steady-state (plateau) concentration?
A) 8 hours
B) 16 hours
C) 24 hours
D) 40 hours (5 half-lives)
Answer: D
Rationale: It takes approximately 4–5 half-lives to reach steady-state (plateau)
concentration. 5 × 8 hours = 40 hours. At steady-state, the rate of drug
administration equals the rate of elimination.
4. The CYP450 enzyme system is primarily located in which organ and is
responsible for:
A) The liver; Phase I metabolism (oxidation, reduction, hydrolysis)
B) The kidneys; filtration
C) The lungs; gas exchange
D) The intestines; absorption
Answer: A
Rationale: The Cytochrome P450 (CYP) enzyme system is predominantly located in
the liver's endoplasmic reticulum. It catalyzes Phase I reactions, which introduce a
reactive functional group onto the drug molecule, preparing it for Phase II
conjugation and elimination.
5. A patient on warfarin is started on a drug that strongly inhibits CYP2C9. What
is the expected clinical outcome?
A) Warfarin will be metabolized faster, leading to reduced anticoagulation
B) Warfarin will be metabolized slower, leading to increased INR and bleeding risk
C) No change in warfarin levels
D) Warfarin will be excreted faster
Answer: B
Rationale: Warfarin is metabolized by CYP2C9. If this enzyme is inhibited, warfarin
metabolism decreases, leading to higher plasma concentrations. This increases the
, Page |3
patient's INR (International Normalized Ratio) and significantly raises the risk of
major bleeding.
6. A drug has a volume of distribution (Vd) of 10,000 L. This indicates that the
drug is:
A) Highly bound to plasma proteins
B) Highly tissue-bound and widely distributed into extravascular tissues
C) Primarily confined to the vascular space
D) Excreted rapidly
Answer: B
Rationale: Volume of distribution (Vd) is a theoretical volume that relates the
amount of drug in the body to the plasma concentration. A very high Vd (like
10,000 L) indicates that the drug is extensively distributed into tissues (e.g., fat,
muscle, organs) and is not staying in the blood. Examples include chloroquine and
digoxin.
7. Which of the following is the most reliable indicator of hepatic drug
metabolism capacity in a patient?
A) Serum creatinine
B) AST and ALT (liver enzymes)
C) Albumin and bilirubin levels (or a comprehensive liver function panel)
D) White blood cell count
Answer: C
Rationale: Hepatic metabolism capacity is best assessed using a combination of
tests including: albumin (synthesized by the liver), bilirubin (excreted by the liver),
and prothrombin time (PT) / INR. AST/ALT indicate hepatocellular injury, but
albumin and bilirubin reflect the liver's synthetic and excretory function, which are
more directly related to drug metabolism capacity.
8. A drug's clearance is defined as:
A) The volume of blood from which the drug is completely removed per unit time
(e.g., mL/min)
B) The time it takes for the drug concentration to decrease by half
NUR 521 Advanced Pharmacology – Complete Practice
Test Bank (2026)
Instructions: Detailed rationales are provided to reinforce advanced concepts.
EXAM 1: Pharmacokinetics, Pharmacodynamics, & Drug Metabolism
1. A patient with renal impairment is prescribed a drug that is primarily
eliminated unchanged by the kidneys. Which pharmacokinetic parameter will be
most significantly altered?
A) Volume of distribution (Vd)
B) Bioavailability
C) Half-life (t½)
D) Peak plasma concentration (Cmax)
Answer: C
Rationale: Half-life (t½) is directly affected by clearance (CL) and volume of
distribution (Vd): t½ = (0.693 × Vd) / CL. If renal clearance is reduced, the drug's
half-life will increase, leading to accumulation and potential toxicity. This is why
dose adjustments are required in renal impairment.
2. A drug with a high therapeutic index (TI) is characterized by:
A) A narrow margin between the effective dose and the toxic dose
B) A wide margin between the effective dose and the toxic dose (e.g., TI > 10)
C) A low potency
D) A short half-life
Answer: B
Rationale: The therapeutic index (TI) is the ratio of the toxic dose (TD50) to the
effective dose (ED50). A high TI (e.g., penicillin, which has a TI > 100) means the
drug is very safe, as the toxic dose is far higher than the effective dose. A low TI
(e.g., digoxin, warfarin) indicates a narrow safety margin and requires strict
monitoring.
, Page |2
3. A patient is taking a drug with a half-life of 8 hours. Approximately how long
will it take to reach steady-state (plateau) concentration?
A) 8 hours
B) 16 hours
C) 24 hours
D) 40 hours (5 half-lives)
Answer: D
Rationale: It takes approximately 4–5 half-lives to reach steady-state (plateau)
concentration. 5 × 8 hours = 40 hours. At steady-state, the rate of drug
administration equals the rate of elimination.
4. The CYP450 enzyme system is primarily located in which organ and is
responsible for:
A) The liver; Phase I metabolism (oxidation, reduction, hydrolysis)
B) The kidneys; filtration
C) The lungs; gas exchange
D) The intestines; absorption
Answer: A
Rationale: The Cytochrome P450 (CYP) enzyme system is predominantly located in
the liver's endoplasmic reticulum. It catalyzes Phase I reactions, which introduce a
reactive functional group onto the drug molecule, preparing it for Phase II
conjugation and elimination.
5. A patient on warfarin is started on a drug that strongly inhibits CYP2C9. What
is the expected clinical outcome?
A) Warfarin will be metabolized faster, leading to reduced anticoagulation
B) Warfarin will be metabolized slower, leading to increased INR and bleeding risk
C) No change in warfarin levels
D) Warfarin will be excreted faster
Answer: B
Rationale: Warfarin is metabolized by CYP2C9. If this enzyme is inhibited, warfarin
metabolism decreases, leading to higher plasma concentrations. This increases the
, Page |3
patient's INR (International Normalized Ratio) and significantly raises the risk of
major bleeding.
6. A drug has a volume of distribution (Vd) of 10,000 L. This indicates that the
drug is:
A) Highly bound to plasma proteins
B) Highly tissue-bound and widely distributed into extravascular tissues
C) Primarily confined to the vascular space
D) Excreted rapidly
Answer: B
Rationale: Volume of distribution (Vd) is a theoretical volume that relates the
amount of drug in the body to the plasma concentration. A very high Vd (like
10,000 L) indicates that the drug is extensively distributed into tissues (e.g., fat,
muscle, organs) and is not staying in the blood. Examples include chloroquine and
digoxin.
7. Which of the following is the most reliable indicator of hepatic drug
metabolism capacity in a patient?
A) Serum creatinine
B) AST and ALT (liver enzymes)
C) Albumin and bilirubin levels (or a comprehensive liver function panel)
D) White blood cell count
Answer: C
Rationale: Hepatic metabolism capacity is best assessed using a combination of
tests including: albumin (synthesized by the liver), bilirubin (excreted by the liver),
and prothrombin time (PT) / INR. AST/ALT indicate hepatocellular injury, but
albumin and bilirubin reflect the liver's synthetic and excretory function, which are
more directly related to drug metabolism capacity.
8. A drug's clearance is defined as:
A) The volume of blood from which the drug is completely removed per unit time
(e.g., mL/min)
B) The time it takes for the drug concentration to decrease by half
